Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,032 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
Clayton R, Ohagen A, Nicol F, Del Vecchio AM, Jonckers TH, Goethals O, Van Loock M, Michiels L, Grigsby J, Xu Z, Zhang YP, Gutshall LL, Cunningham M, Jiang H, Bola S, Sarisky RT, Hertogs K. Clayton R, et al. Antiviral Res. 2009 Nov;84(2):142-9. doi: 10.1016/j.antiviral.2009.08.003. Epub 2009 Aug 20. Antiviral Res. 2009. PMID: 19699239
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, Feyaerts M, Verheyen A, Smits V, Van Loock M, Hertogs K, Schols D, Clayton RF. Goethals O, et al. Antiviral Res. 2011 Aug;91(2):167-76. doi: 10.1016/j.antiviral.2011.05.011. Epub 2011 Jun 12. Antiviral Res. 2011. PMID: 21669228
Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells.
Clayton R, Ohagen A, Goethals O, Smets A, Van Loock M, Michiels L, Kennedy-Johnston E, Cunningham M, Jiang H, Bola S, Gutshall L, Gunn G, Del Vecchio A, Sarisky R, Hallenberger S, Hertogs K. Clayton R, et al. J Virol Methods. 2007 Jan;139(1):17-23. doi: 10.1016/j.jviromet.2006.08.017. Epub 2006 Oct 10. J Virol Methods. 2007. PMID: 17034868
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.
Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G, Jochmans D, Vermeire K, Schols D, Hallenberger S, Hertogs K. Goethals O, et al. Among authors: clayton r. J Virol. 2008 Nov;82(21):10366-74. doi: 10.1128/JVI.00470-08. Epub 2008 Aug 20. J Virol. 2008. PMID: 18715920 Free PMC article.
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R. Goethals O, et al. Among authors: clayton r. Virology. 2010 Jul 5;402(2):338-46. doi: 10.1016/j.virol.2010.03.034. Epub 2010 Apr 24. Virology. 2010. PMID: 20421122 Free article.
1,032 results